Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical

Enzon CEO Profited While Stock Languished, DellaCamera Charges

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Shareholder activist hedge fund calls a “Town Hall” to justify ousting the CEO as part of an unusual maneuver to solicit shareholder votes.

You may also be interested in...



People In The News: Tracking The Latest Industry Personnel Moves

Presidents and CEOs

People In The News: Tracking The Latest Industry Personnel Moves

Presidents and CEOs

Second Time A Charm? Enzon Sells Biotech Business To Italian Pharma

One year after a failed effort to sell off its biotech business, Enzon will bring in $300 million by selling its four specialty drugs to Sigma-Tau.

Table

View full table

Topics

Tags:
BioPharmaceutical
UsernamePublicRestriction

Register

PS063835

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By